- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Rh testing or immunoglobulin administration following induced first-trimester abortion not necessary: JAMA
![Rh testing or immunoglobulin administration following induced first-trimester abortion not necessary: JAMA Rh testing or immunoglobulin administration following induced first-trimester abortion not necessary: JAMA](https://medicaldialogues.in/h-upload/2023/01/17/750x450_198501-abortion.webp)
Rh testing and therapy are not indicated before to 12 weeks' gestation since induced first-trimester abortion is not a risk factor for Rh sensitization, says an article published in the Journal of American Medical Association.
Rh immunoglobulin is not essential until 12 weeks of pregnancy, according to population-level statistics, however there is little clinical support for this idea. As a result, recommendations change, leaving the dangers and advantages of Rh testing and therapy unclear. This study by Sarah Horvath and colleagues assessed how frequently maternal exposure to fetal red blood cells (fRBCs) in induced first-trimester abortion surpasses the most conservative reported threshold for Rh sensitization.
High-throughput flow cytometry was used to identify circulating fRBCs in matched maternal blood samples taken before and after an induced first-trimester abortion (either medically or surgically). Before 12 weeks and 0 days of gestation, those who had an induced first-trimester abortion were included. 506 patients who experienced either a medical (n = 319 [63.0%]) or procedural (n = 187 [37.0%]) abortion were able to provide paired blood samples. The percentage of subjects with fRBC counts over the sensitization threshold (125 fRBCs/5 million total RBCs) following an induced first-trimester abortion served as the main outcome.
The key findings of this study were:
The average (SD) age of the 506 participants was 27.4 (5.5) years; 313 (61.9%) of them were Black, and 123 (24.3%) were White.
Three of the 506 participants had high fRBC levels at the beginning of the study, and one of these patients also had a high fRBC count after the abortion.
After an induced first-trimester abortion, no additional subjects showed raised fRBC counts beyond the sensitization threshold.
The 99th percentile and higher 95th percentile had values of 24 and 35.6 fRBCs, respectively, with the median change from baseline being 0 fRBCs.
No other baseline attribute was substantially linked with post-abortion fRBC count, despite the fact that there was a considerable correlation between the pre-abortion and post-abortion fRBC counts.
Reference:
Horvath, S., Huang, Z.-Y., Koelper, N. C., Martinez, C., Tsao, P. Y., Zhao, L., Goldberg, A. B., Hannum, C., Putt, M. E., Luning Prak, E. T., & Schreiber, C. A. (2023). Induced Abortion and the Risk of Rh Sensitization. In JAMA (Vol. 330, Issue 12, p. 1167). American Medical Association (AMA). https://doi.org/10.1001/jama.2023.16953
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751